semaglutide type 1 diabetes randomized trial 2024 in patients with overweight or obesity and chronic kidney disease without diabetes: a double-blind placebo-controlled clinical The GLP-1 Clinical Trial Landscape

Twist1 in podocytes ameliorates podocyte injury and proteinuria by limiting CCL2-dependent macrophage infiltration

The magnitude of early weight was found to be a predictor of super responder status in both the exenatide and diet treatment groups

A practical immune-support IV for stress, travel, recurrent illness patterns, and poor oral nutrient tolerance

Such drastic differences in microbiota compositions across geography highlight the challenges in using gut microbiota compositions as a sole diagnostic biomarker

Rebound or Retention: A Meta-Analysis of Weight Regain After Discontinuation of GLP-1 Receptor Agonists and Other Anti-obesity Drugs

CK, through the reduction of TGF1 and inhibiting its downstream pathway, RhoA/ROCK, ameliorates the G/F-actin ratio, which under glucotoxicity creates a barrier for GLP-1 secretion